<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: competitors", fill: "#f00"},
{source: "6: competitors", target: "9: operations", fill: "#0000cd"},
{source: "9: operations", target: "9: customers hiring practices", fill: "#0000cd"},
{source: "9: customers hiring practices", target: "9: factors beyond", fill: "#0000cd"},
{source: "9: operations", target: "12: proprietary", fill: "#3cb371"},
{source: "12: proprietary", target: "12: technology", fill: "#3cb371"},
{source: "12: proprietary", target: "13: rely primarily on", fill: "#915f6d"},
{source: "13: rely primarily on", target: "13: combination", fill: "#915f6d"},
{source: "13: combination", target: "13: trade secrets patents", fill: "#915f6d"},
{source: "13: trade secrets patents", target: "13: confidentiality procedures", fill: "#915f6d"},
{source: "13: confidentiality procedures", target: "13: technology", fill: "#915f6d"},
{source: "13: rely primarily on", target: "23: key man life insurance", fill: "#339"},
{source: "23: key man life insurance", target: "23: key personnel", fill: "#339"},
{source: "23: key man life insurance", target: "26: most critical", fill: "#fe28a2"},
{source: "26: most critical", target: "26: radiolabeled drugs which", fill: "#fe28a2"},
{source: "26: radiolabeled drugs which", target: "26: purchases from", fill: "#fe28a2"},
{source: "26: purchases from", target: "26: single supplier although", fill: "#fe28a2"},
{source: "26: single supplier although", target: "26: radiolabeled drugs", fill: "#fe28a2"},
{source: "26: most critical", target: "29: Companys ", fill: "#008000"},
{source: "29: Companys ", target: "29: alternative supplier", fill: "#008000"},
{source: "29: alternative supplier", target: "29: radiolabeled drugs", fill: "#008000"},
{source: "29: radiolabeled drugs", target: "29: provide such radiolabeled drugs at", fill: "#008000"},
{source: "29: provide such radiolabeled drugs at", target: "29: supplies from such", fill: "#008000"},
{source: "29: supplies from such", target: "29: exhaustion", fill: "#008000"},
{source: "29: exhaustion", target: "29: Companys ", fill: "#008000"},
{source: "29: Companys ", target: "29: current supply on hand could", fill: "#008000"},
{source: "29: current supply on hand could", target: "29: deferred sales", fill: "#008000"},
{source: "29: Companys ", target: "30: stock options", fill: "#e9d66b"},
{source: "30: stock options", target: "30: restricted stock", fill: "#e9d66b"},
{source: "30: restricted stock", target: "30: future periods", fill: "#e9d66b"},
{source: "30: stock options", target: "32: addresses", fill: "#efbbcc"},
{source: "32: addresses", target: "32: accounting", fill: "#efbbcc"},
{source: "32: accounting", target: "32: employee stock options", fill: "#efbbcc"},
{source: "32: employee stock options", target: "32: payment transactions", fill: "#efbbcc"},
{source: "32: addresses", target: "33: statement eliminates", fill: "#556b2f"},
{source: "33: statement eliminates", target: "33: transactions", fill: "#556b2f"},
{source: "33: transactions", target: "33: Accounting for Stock Issued to Employees ", fill: "#556b2f"},
{source: "33: statement eliminates", target: "34: accounting treatment", fill: "#7851a9"},
{source: "34: accounting treatment", target: "34: expenses beginning", fill: "#7851a9"},
{source: "34: expenses beginning", target: "34: new options", fill: "#7851a9"},
{source: "34: new options", target: "34: sharebased awards", fill: "#7851a9"},
{source: "34: sharebased awards", target: "34: may thereafter", fill: "#7851a9"},
{source: "34: may thereafter", target: "34: granted which would decrease", fill: "#7851a9"},
{source: "34: granted which would decrease", target: "34: could adversely affect", fill: "#7851a9"},
{source: "34: could adversely affect", target: "34: market price", fill: "#7851a9"},
{source: "34: accounting treatment", target: "39: addition rules", fill: "#ffcba4"},
{source: "39: addition rules", target: "39: shareholder approval", fill: "#ffcba4"},
{source: "39: shareholder approval", target: "39: stock option", fill: "#ffcba4"},
{source: "39: stock option", target: "39: difficult", fill: "#ffcba4"},
{source: "39: difficult", target: "39: grant options", fill: "#ffcba4"},
{source: "39: addition rules", target: "41: potential risks", fill: "#ff6961"},
{source: "41: potential risks", target: "41: will incur costs as", fill: "#ff6961"},
{source: "41: will incur costs as", target: "41: internal control testing", fill: "#ff6961"},
{source: "41: internal control testing", target: "41: evaluation process mandated by", fill: "#ff6961"},
{source: "41: evaluation process mandated by", target: "41: SarbanesOxley Act ", fill: "#ff6961"},
{source: "41: potential risks", target: "42: Commencing ", fill: "#800080"},
{source: "42: Commencing ", target: "42: effectiveness", fill: "#800080"},
{source: "42: effectiveness", target: "42: SarbanesOxley Act ", fill: "#800080"},
{source: "42: Commencing ", target: "48: protect us from", fill: "#195905"},
{source: "48: protect us from", target: "48: omissions liability", fill: "#195905"},
{source: "48: omissions liability", target: "48: future errors", fill: "#195905"},
{source: "48: future errors", target: "48: omissions insurance will", fill: "#195905"},
{source: "48: omissions insurance will", target: "48: reasonable cost", fill: "#195905"},
{source: "48: protect us from", target: "START_HERE", fill: "#195905"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent">Patent</a></td>
      <td>A patient is any recipient of health care services that are performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, optometrist, dentist, veterinarian, or other health care provider.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_London_Bridge">Operation London Bridge</a></td>
      <td>Operation London Bridge (also known by its code phrase London Bridge is Down) is the plan for what will happen in the United Kingdom on and immediately after the death of Queen Elizabeth II. It includes planning for the announcement of her death, the period of official mourning, and the details of her state funeral. Some critical decisions relating to the plan have been made by the Queen herself, although some can only be made by her successor, Charles, after her death.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/N,N-Dimethyltryptamine">N,N-Dimethyltryptamine</a></td>
      <td>N,N-Dimethyltryptamine (DMT or N,N-DMT) is a substituted tryptamine that occurs in many plants and animals, including human beings, and which is both a derivative and a structural analog of tryptamine. It is used as a recreational psychedelic drug and prepared by various cultures for ritual purposes as an entheogen.DMT has a rapid onset, intense effects, and a relatively short duration of action.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Autoradiograph">Autoradiograph</a></td>
      <td>An autoradiograph is an image on an x-ray film or nuclear emulsion produced by the pattern of decay emissions (e.g., beta particles or gamma rays) from a distribution of a radioactive substance. Alternatively, the autoradiograph is also available as a digital image (digital autoradiography), due to the recent development of scintillation gas detectors or rare earth phosphorimaging systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nucleotide">Nucleotide</a></td>
      <td>Nucleotides are organic molecules consisting of a nucleoside and a phosphate. They serve as monomeric units of the nucleic acid polymers – deoxyribonucleic acid (DNA) and ribonucleic acid (RNA),  both of which are essential biomolecules within all life-forms on Earth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Passeig_de_Lluís_Companys,_Barcelona">Passeig de Lluís Companys, Barcelona</a></td>
      <td>Passeig de Lluís Companys (Catalan pronunciation: [pəˈsɛdʒ də ʎuˈis kumˈpaɲs]) is a promenade in the Ciutat Vella and Eixample districts of Barcelona, Catalonia, Spain, and can be seen as an extension of Passeig de Sant Joan. It was named after President Lluís Companys, who was executed in 1940.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estadi_Olímpic_Lluís_Companys">Estadi Olímpic Lluís Companys</a></td>
      <td>Estadi Olímpic Lluís Companys (Catalan pronunciation: [əsˈtaði uˈlimpiɡ ʎuˈis kumˈpaɲs], formerly known as the Estadi Olímpic de Montjuïc and Estadio de Montjuic) is a stadium in Barcelona, Catalonia, Spain. Originally built in 1927 for the 1929 International Exposition in the city (and Barcelona's bid for the 1936 Summer Olympics, which were awarded to Berlin), it was renovated in 1989 to be the main stadium for the 1992 Summer Olympics and 1992 Summer Paralympics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Companys,_procés_a_Catalunya">Companys, procés a Catalunya</a></td>
      <td>Companys, procés a Catalunya (Spanish: Companys, proceso a Cataluña) is a 1979 Spanish Catalan drama film directed by Josep Maria Forn, based on the last months of the life of the President of Catalonia, Lluís Companys, in which he shows his detention by the Nazis and his subsequent execution by the Spanish Francoists. It competed in the Un Certain Regard section at the 1979 Cannes Film Festival.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amazon_(company)">Amazon (company)</a></td>
      <td>Amazon.com, Inc. ( AM-ə-zon) is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Employee_stock_option">Employee stock option</a></td>
      <td>Employee stock options (ESO) is a label that refers to compensation contracts between an employer and an employee that carries some characteristics of financial options.\nEmployee stock options are commonly viewed as an internal agreement providing the possibility to participate in the share capital of a company, granted by the company to an employee as part of the employee's remuneration package.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-qualified_stock_option">Non-qualified stock option</a></td>
      <td>Non-qualified stock options (typically abbreviated NSO or NQSO) are stock options which do not qualify for the special treatment accorded to incentive stock options.\nIncentive stock options (ISOs) are only available for employees and other restrictions apply for them.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_accounting">Management accounting</a></td>
      <td>In management accounting or managerial accounting, managers use accounting information in decision-making and to assist in the management and performance of their control functions.\n\n\n== Definition ==\n\nOne simple definition of management accounting is the provision of financial and non-financial decision-making information to managers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_dilution">Stock dilution</a></td>
      <td>Stock dilution, also known as equity dilution,  is the decrease in existing shareholders' ownership percentage of a company as a result of the company issuing new equity. New equity increases the total shares outstanding which has a dilutive effect on the ownership percentage of existing shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Golden_handcuffs">Golden handcuffs</a></td>
      <td>Golden handcuffs, a phrase first recorded in 1976, refers to financial allurements and benefits that have the objective to encourage highly compensated employees to remain within a company or organization instead of moving from company to company (or organization to organization) (opposite of a golden parachute). Golden handcuffs come in different forms, such as employee stock options or restricted stock, which endow only when the employee has been with the company or organization for a certain number of years, and contractual agreements, consisting of bonuses or other forms of benefits which must be repaid to the company if the employee leaves before the date agreed on.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Credit_rating">Credit rating</a></td>
      <td>A credit rating is an evaluation of the credit risk of a prospective debtor (an individual, a business, company or a government), predicting their ability to pay back the debt, and  an implicit forecast of the likelihood of the debtor defaulting.\nThe credit rating represents an evaluation of a credit rating agency of the qualitative and quantitative information for the prospective debtor, including information provided by the prospective debtor and other non-public information obtained by the credit rating agency's analysts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sand_eel">Sand eel</a></td>
      <td>Sand eel or sandeel is the common name used for a considerable number of species of fish.  While they are not true eels, they are eel-like in their appearance and can grow up to 30 centimetres (12 in) in length.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/For_Love_or_Money_(2014_film)">For Love or Money (2014 film)</a></td>
      <td>For Love or Money (Chinese: 露水红颜) is a Chinese romance film based on Hong Kong novelist Amy Cheung's 2006 novel of the same name. The film was directed by Gao Xixi and starring Liu Yifei and Rain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Investor_relations">Investor relations</a></td>
      <td>Investor relations (IR) is a strategic management responsibility that is capable of integrating finance, communication, marketing and securities law compliance to enable the most effective two-way communication between a company, the financial community, and other constituencies, which ultimately contributes to a company's securities achieving fair valuation. (Adopted by the NIRI board of directors, March 2003.)  The term describes the department of a company devoted to handling inquiries from shareholders and investors, as well as others who might be interested in a company's stock or financial stability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Condom_effectiveness">Condom effectiveness</a></td>
      <td>Condom effectiveness is how effective condoms are at preventing STDs and pregnancy. Correctly using male condoms and other barriers like female condoms and dental dams, every time, can reduce (though not eliminate) the risk of sexually transmitted infections  (STIs), including human immunodeficiency virus (HIV) and viral hepatitis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Organizational_effectiveness">Organizational effectiveness</a></td>
      <td>Organizational effectiveness is a concept organizations use to gauge how effective they are at reaching intended outcomes.\nOrganisational effectiveness embodies the degree to which firms achieve the goals they have decided upon, a question that draws on several different factors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jambhala">Jambhala</a></td>
      <td>Jambhala (also known as Dzambhala, Dzambala, Zambala or Jambala) is the God of Fortune and Wealth and appropriately a member of the Jewel Family (see Ratnasambhava). He is sometimes equated with the Hindu deity Kubera.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PSYCHEMEDICS CORP      Item 1A Risk Factors     This report contains forward-looking statements that <font color="blue">involve risks</font> and     <font color="blue">uncertainties</font>,  <font color="blue">such as statements</font> of our objectives, expectations and     <font color="blue">intentions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">cautionary</font>                                         10       _________________________________________________________________    [42]Table of <font color="blue">Contents       </font>statements  made  in  this  report should be read as applicable to all     forward-looking statements wherever they appear in this report</td>
    </tr>
    <tr>
      <td>Our actual     results <font color="blue">could differ materially from</font> those <font color="blue">discussed herein</font></td>
    </tr>
    <tr>
      <td>Factors that     could cause or contribute to <font color="blue">such differences</font> include those discussed below,     as well as those <font color="blue">discussed elsewhere</font> in this report</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>may develop products that <font color="blue">compete with</font> our products and some of     these <font color="blue">companies may</font> be larger and <font color="blue">better capitalized than</font> we are</td>
    </tr>
    <tr>
      <td>Many  of our <font color="blue">competitors</font> and potential <font color="blue">competitors</font> are larger and have     greater financial resources than we do and offer a range of products broader     than our products</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">companies with which</font> we now compete or may     compete in the <font color="blue">future may</font> develop more extensive research and marketing     <font color="blue">capabilities</font> and <font color="blue">greater technical</font> and <font color="blue">personnel resources than</font> we do, and     <font color="blue">may become better positioned</font> to compete in an <font color="blue">evolving industry</font></td>
    </tr>
    <tr>
      <td>Failure to     compete <font color="blue">successfully</font> <font color="blue">could harm</font> our business and prospects</td>
    </tr>
    <tr>
      <td>Our  results  of  <font color="blue">operations</font>  are  subject in part to variation in our     customers’ hiring practices and other <font color="blue">factors beyond</font> our control</td>
    </tr>
    <tr>
      <td>Our  results of <font color="blue">operations</font> have been and <font color="blue">may continue</font> to be subject to     variation in our customer’s hiring practices, which in turn is <font color="blue">dependent</font> to     a  large extent on the <font color="blue">general condition</font> of the economy</td>
    </tr>
    <tr>
      <td>Results for a     particular quarter may vary due to a number of factors, including:       •   <font color="blue">economic conditions</font> in our markets in general;         •   <font color="blue">economic conditions</font> affecting our customers and their particular     <font color="blue">industries</font>;         •   the <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">product enhancements by us</font> or our     <font color="blue">competitors</font>; and         •   pricing and other <font color="blue">competitive conditions</font></td>
    </tr>
    <tr>
      <td>Our business could be harmed if we are unable to protect our <font color="blue">proprietary</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely primarily on</font> a <font color="blue">combination</font> of trade secrets, patents and trademark     laws and <font color="blue">confidentiality procedures</font> to protect our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Despite these     precautions, unauthorized third parties may infringe or <font color="blue">copy portions</font> of our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may in<font color="blue">dependent</font>ly develop similar <font color="blue">technology</font>     that our patents do not cover</td>
    </tr>
    <tr>
      <td>In addition, because <font color="blue">patent applications</font> in     the <font color="blue">United States </font>are not publicly disclosed until either (1) 18 months     after the <font color="blue">application filing date</font> or (2) the <font color="blue">publication date</font> of an issued     patent wherein applicant(s) seek only US patent protection, applications not     yet disclosed may have <font color="blue">been filed which</font> relate to our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Moreover,     there is a risk that <font color="blue">foreign <font color="blue">intellectual property laws</font> will</font> not protect our     intellectual  property  rights  to  the  same  extent as <font color="blue">United States </font>    <font color="blue">intellectual property laws</font></td>
    </tr>
    <tr>
      <td>In the absence of <font color="blue">significant</font> patent protection,     we  may be vulnerable to <font color="blue">competitors</font> who attempt to copy our products,     processes or <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our  future  success  <font color="blue">will depend on</font> the <font color="blue">continued services</font> of our key     personnel</td>
    </tr>
    <tr>
      <td>The  loss  of any of our <font color="blue">key personnel</font>, particularly our key sales and     marketing personnel, <font color="blue">could harm</font> our business and prospects</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will</font>     also  depend  upon  our  ability to attract and retain other qualified     managerial and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to attract and retain     <font color="blue">personnel necessary</font> for the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>We do not have any     <font color="blue">key man life insurance</font> for any of our officers or other <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [43]Table of <font color="blue">Contents       </font>Our <font color="blue">reliance on one supplier</font> for <font color="blue">certain raw materials used</font> in our testing     <font color="blue">procedures <font color="blue">could harm</font></font> our business and prospects</td>
    </tr>
    <tr>
      <td>Since  its  inception, the Company has <font color="blue">purchased raw materials</font> for its     <font color="blue">laboratory services from outside suppliers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">most critical</font> of these raw     materials are the radio-labeled drugs, which the Company <font color="blue">purchases from</font> a     single supplier, although other suppliers of radio-labeled drugs exist</td>
    </tr>
    <tr>
      <td>The     Company  has  <font color="blue">entered into</font> an <font color="blue">agreement with</font> its <font color="blue">principal supplier</font> to     purchase certain <font color="blue">proprietary</font> information regarding the <font color="blue">manufacture</font> of such     radio-labeled drugs owned by the supplier in the event that the supplier     ceases  to  be able to supply such radio-labeled drugs to the Company</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font><font color="blue">alternative sources</font> of supply of the radio-labeled drugs could     <font color="blue">involve delays</font> and other costs; however, the Company maintains a surplus     supply</td>
    </tr>
    <tr>
      <td>The failure of the Company’s primary or any <font color="blue">alternative supplier</font> of     radio-labeled drugs to provide such radio-labeled drugs at an acceptable     price,  or  an  interruption  of <font color="blue">supplies from such</font> a supplier and the     <font color="blue">exhaustion</font> of the Company’s <font color="blue">current supply on hand could</font> result in lost or     <font color="blue">deferred sales</font></td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">significant</font> stock-based compensation charges related to certain     <font color="blue"><font color="blue">stock option</font>s</font> and <font color="blue">restricted stock</font> in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>The Financial Accounting Standards Board (FASB) issued in <font color="blue">December </font>2004     <font color="blue">Statement </font>of Financial Accounting Standards (SFAS) Nodtta 123R, Share-Based     Payment, an <font color="blue">amendment</font> <font color="blue">of FASB Statements Nos</font></td>
    </tr>
    <tr>
      <td>123 and 95, that <font color="blue">addresses</font> the     <font color="blue">accounting</font>  treatment for employee <font color="blue"><font color="blue">stock option</font>s</font> and other share-based     <font color="blue">payment <font color="blue">transactions</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">statement eliminates</font> the ability to account for     share-based compensation <font color="blue">transactions</font> using Accounting Principles Board     (APB) Opinion Nodtta 25, Accounting for Stock Issued to Employees, and requires     that such <font color="blue">transactions</font> be accounted for using a fair-value-based method and     recognized as expenses</td>
    </tr>
    <tr>
      <td>The statement and the change in <font color="blue">accounting</font> treatment     may result in our reporting increased operating <font color="blue">expenses beginning</font> in 2006     as a result of <font color="blue">new options</font> or other share-based awards that <font color="blue">may thereafter</font>     be <font color="blue">granted which would decrease</font> any reported net income or increase any     reported net loss, and <font color="blue">could <font color="blue">adversely affect</font></font> the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td><font color="blue">Recently </font>issued rules and/or regulations related to <font color="blue">equity compensation</font>     <font color="blue">could <font color="blue">adversely affect</font></font> our ability to attract and retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">historically</font>  used  <font color="blue"><font color="blue">stock option</font>s</font> and other long-term equity     <font color="blue">incentives as</font> a <font color="blue">fundamental</font> component of our <font color="blue">compensation packages</font></td>
    </tr>
    <tr>
      <td>We     believe that <font color="blue"><font color="blue">equity awards</font> directly motivate</font> our employees to maximize     long-term stockholder value and, through the use of vesting, encourage     employees  to <font color="blue">remain with us</font></td>
    </tr>
    <tr>
      <td>The recent changes in the <font color="blue">accounting</font> for     employee <font color="blue"><font color="blue">stock option</font>s</font> and other share-based payments under <font color="blue">Statement </font>123R     require us to record a charge to earnings for new and <font color="blue">unvested employee</font>     <font color="blue"><font color="blue">stock option</font> grants beginning</font> in 2006</td>
    </tr>
    <tr>
      <td>In addition, rules of the American     Stock Exchange that require <font color="blue">shareholder approval</font> for <font color="blue">stock option</font> and other     equity-based compensation plans, could make it more <font color="blue">difficult</font> for us to     <font color="blue">grant options</font> or other equity-based awards to employees in the future</td>
    </tr>
    <tr>
      <td>If     these <font color="blue">new regulations</font> make it more <font color="blue">difficult</font> or expensive to <font color="blue">grant stock</font>     options or other <font color="blue">equity awards</font> to employees, we may need to change our     <font color="blue">equity compensation</font> strategy and we may find it <font color="blue">difficult</font> to attract, retain     and motivate employees, each of <font color="blue">which could materially</font> and <font color="blue">adversely affect</font>     our business</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [44]Table of <font color="blue">Contents       </font>We are exposed to <font color="blue">potential risks</font> and we <font color="blue">will incur costs as</font> a result of the     <font color="blue">internal control testing</font> and <font color="blue"><font color="blue">evaluation</font> process mandated by</font> Section 404 of     the Sarbanes-Oxley Act of 2002</td>
    </tr>
    <tr>
      <td><font color="blue">Commencing </font>in 2007, we are required to assess the <font color="blue">effectiveness</font> of our     internal control over financial reporting as required by Section 404 of the     Sarbanes-Oxley Act of 2002</td>
    </tr>
    <tr>
      <td><font color="blue">Documenting </font>and testing the <font color="blue">effectiveness</font> of our     internal control over financial reporting will cause us to incur <font color="blue">significant</font>     costs, including increased <font color="blue">accounting</font> fees and increased staffing levels</td>
    </tr>
    <tr>
      <td>It     should  be  noted that the majority of our <font color="blue">documentation</font> work has been     completed</td>
    </tr>
    <tr>
      <td>If we fail to complete the Sarbanes-Oxley 404 <font color="blue">evaluation</font> in a <font color="blue">timely manner</font>,     or if our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm cannot attest in a     <font color="blue">timely manner</font> to our <font color="blue">evaluation</font>, we could be subject to <font color="blue">regulatory scrutiny</font>     and a loss of <font color="blue">public confidence</font> in our <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>In addition, any     failure to implement required new or <font color="blue">improved controls</font>, or <font color="blue">difficult</font>ies     <font color="blue">encountered</font> in their implementation, <font color="blue">could harm</font> our operating results or     cause us to fail to meet our reporting <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>We intend to devote     substantial  time and incur substantial costs, as necessary, to ensure     <font color="blue">ongoing compliance</font></td>
    </tr>
    <tr>
      <td>There is a risk that our <font color="blue">insurance will</font> not be sufficient to <font color="blue">protect us from</font>     errors and <font color="blue">omissions liability</font> or other claims, or that in the <font color="blue">future errors</font>     and <font color="blue">omissions <font color="blue">insurance will</font></font> not be available to us at a <font color="blue">reasonable cost</font>, if     at all</td>
    </tr>
    <tr>
      <td>We maintain errors and omissions and     <font color="blue">general liability insurance</font> subject to <font color="blue">deductibles</font> and <font color="blue">exclusions</font></td>
    </tr>
    <tr>
      <td>There is     a risk that our <font color="blue">insurance will</font> not be sufficient to <font color="blue">protect us from</font> all such     possible  claims</td>
    </tr>
    <tr>
      <td>An  under-insured or uninsured claim <font color="blue">could harm</font> our     operating results or <font color="blue">financial condition</font></td>
    </tr>
  </tbody>
</table>